L Sedlacek1, B Graf2, C Schwarz3, F Albert4, S Peter5, B Würstl6, S Wagner7, M Klotz8, A Becker9, G Haase10, G Laniado11, B Kahl12, S Suerbaum13, M Seibold14, K Tintelnot15. 1. Medizinische Hochschule Hannover, Medizinische Mikrobiologie und Krankenhaushygiene, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Electronic address: Sedlacek.Ludwig@mh-hannover.de. 2. Labor Berlin - Charité Vivantes GmbH, Mikrobiologie/Mykologie, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address: barbara.graf@laborberlin.com. 3. Christiane Herzog-Zentrum/Mukoviszidose, Klinik für Pädiatrie m.S. Pneumologie u. Immunologie, Sylter Str. 2, 13353 Berlin, Germany. Electronic address: carsten.schwarz@charite.de. 4. Universitätsklinikum Erlangen, Mikrobiologisches Institut, Wasserturmstraße 3-5, 91054 Erlangen, Germany. Electronic address: frauke.albert@labor-limbach-nuernberg.de. 5. Universitätsklinikum Tübingen, Institut für Medizinische Mikrobiologie und Hygiene, Elfriede-Aulhorn-Straße 6, 72076 Tübingen, Germany. Electronic address: silke.peter@med.uni-tuebingen.de. 6. Max von Pettenkofer-Institut, Medizinische Mikrobiologie, Pettenkoferstraße 9a, 80336 München, Germany. Electronic address: b.wuerstl@hygconcept.de. 7. Helios Klinik Emil von Behring, Institut für Mikrobiologie, Immunologie und Labormedizin, Walterhöferstraße 11, 14165 Berlin, Germany. Electronic address: sonja.wagner@helios-kliniken.de. 8. Universitätskliniken des Saarlandes, Institut für Med. Mikrobiologie und Hygiene, Kirrberger Straße, Gebäude 43, 66421 Homburg/Saar, Germany. Electronic address: michael.klotz@uks.eu. 9. Städtisches Klinikum Karlsruhe, Zentralinstitut für Laboratoriumsmedizin, Mikrobiologie und Transfusionsmedizin, Moltkestraße 90, 76133 Karlsruhe, Germany. Electronic address: andrea.becker@klinikum-karlsruhe.de. 10. RWTH Aachen, University Hospital, Institut für Med. Mikrobiologie, Pauwelsstraße 30, 52074 Aachen, Germany. Electronic address: ghaase@ukaachen.de. 11. Dr. v. Haunersches Kinderspital, Bakteriologisches Labor, Ludwig Maximilian Universität, Lindwurmstr. 4, 80337 München, Germany. Electronic address: gudrun.laniado@med.uni-muenchen.de. 12. Universitätsklinikum Münster, Institut für Med. Mikrobiologie, Domagkstraße 10, 48149 Münster, Germany. Electronic address: kahl@uni-muenster.de. 13. Medizinische Hochschule Hannover, Medizinische Mikrobiologie und Krankenhaushygiene, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Electronic address: suerbaum.sebastian@mh-hannover.de. 14. Robert Koch-Institut, FG 16 Mykologie, Nordufer 20, 13353 Berlin, Germany. Electronic address: seiboldm@rki.de. 15. Robert Koch-Institut, FG 16 Mykologie, Nordufer 20, 13353 Berlin, Germany. Electronic address: tintelnotk@rki.de.
Abstract
OBJECTIVE: Detection of hyphomycetes of the Scedosporium apiospermum complex and Lomentospora prolificans (Sac-Lp) is not yet standardized. Prevalence rates in patients with cystic fibrosis (CF) and the resistance pattern of these pathogens in Germany are unknown. METHODS: In a one-year prospective study 11 laboratories used a selective medium for isolation of Sac-Lp, examining >11,600 respiratory samples from 2346 patients with CF. Isolates were identified by molecular methods and tested for susceptibility to antifungal drugs. RESULTS: The prevalence of Sac-Lp in patients with CF in Germany varied from 0.0 to 10.5% (mean: 3.1%) among the clinical centres. The benefit of the selective medium SceSel(+) compared to standard media for fungi was documented for >5000 samples. High antifungal resistance was detected in the S. apiospermum complex, and the multiresistance of L. prolificans was confirmed. CONCLUSION: Microbiology laboratories should be aware of these resistant species in patients with CF and consider using a selective medium.
OBJECTIVE: Detection of hyphomycetes of the Scedosporium apiospermum complex and Lomentospora prolificans (Sac-Lp) is not yet standardized. Prevalence rates in patients with cystic fibrosis (CF) and the resistance pattern of these pathogens in Germany are unknown. METHODS: In a one-year prospective study 11 laboratories used a selective medium for isolation of Sac-Lp, examining >11,600 respiratory samples from 2346 patients with CF. Isolates were identified by molecular methods and tested for susceptibility to antifungal drugs. RESULTS: The prevalence of Sac-Lp in patients with CF in Germany varied from 0.0 to 10.5% (mean: 3.1%) among the clinical centres. The benefit of the selective medium SceSel(+) compared to standard media for fungi was documented for >5000 samples. High antifungal resistance was detected in the S. apiospermum complex, and the multiresistance of L. prolificans was confirmed. CONCLUSION: Microbiology laboratories should be aware of these resistant species in patients with CF and consider using a selective medium.
Authors: Gina Hong; Heather B Miller; Sarah Allgood; Richard Lee; Noah Lechtzin; Sean X Zhang Journal: J Clin Microbiol Date: 2017-01-18 Impact factor: 5.948
Authors: Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry Journal: Mycopathologia Date: 2017-07-31 Impact factor: 2.574